TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Ontology highlight
ABSTRACT: Clear cell renal cell carcinoma (ccRCC) is one of the most common urological malignancies. Identifying novel biomarkers and investigating the underlying mechanism of ccRCC development will be crucial to the management and treatment of ccRCC in patients. Thymosin b10 (TMSB10), a member of the thymosin family, is involved in various physiological processes, including tissue regeneration and inflammatory regulation. Moreover, it has been found to be upregulated in many types of carcinoma. However, its roles in ccRCC remain to be elucidated. The present study aimed to explore the expression of TMSB10 in ccRCC through mining The Cancer Genome Atlas (TCGA) and Oncomine databases, and to investigate the association between TMSB10 expression and clinicopathological factors. Furthermore, immunohist
SUBMITTER: Pan Q
PROVIDER: S-EPMC7115359 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
ACCESS DATA